Micro-chamber Covalent Linking for Matched Antibody Libraries
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibody therapies face challenges in generating antibodies suitable for treating, preventing, and diagnosing various disorders, as existing methods lack efficient approaches for matching heavy and light chain variable regions for therapeutic applications.
Innovation Solution
A method involving the isolation and covalent linking of heavy and light chain double-stranded cDNAs within a production micro-chamber to create nucleic acid sequences encoding matched antibody or T-cell receptor variable regions, facilitating the production of functional antigen-binding molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional methods are used to generate antibody libraries, then a wide variety of antibodies can be obtained, but the heavy and light chain variable regions cannot be ensured to be matched
Solution Approach 1:
The method segments the antibody generation process into separate heavy chain and light chain variable region isolation steps, followed by controlled covalent linking. This segmentation allows independent optimization of each chain's diversity while ensuring their subsequent matched pairing through the micro-chamber ligation process.
Solution Approach 2:
The patent introduces an intermediary micro-chamber system that facilitates the controlled covalent linking of heavy and light chain variable regions. This intermediary structure enables precise matching of HCVR and LCVR sequences while maintaining the ability to generate diverse antibody combinations through systematic pairing.
2Reliability
If isolated cell reaction sites are used for cDNA synthesis, then contamination from other cells is prevented, but the complexity of the process increases
Solution Approach 1:
The method employs nested micro-chambers where cell isolation reaction sites are contained within larger production reaction sites, which are themselves part of an array system. This nesting structure enables sequential processing steps while maintaining physical isolation, thereby ensuring nucleic acid purity without requiring complex external containment systems.
Solution Approach 2:
The patent utilizes parameter changes in the form of spatial confinement within micro-chambers of specific dimensions. By controlling the physical parameters of the reaction environment (volume, isolation, and positioning), the system achieves high reliability in nucleic acid sequence purity while managing complexity through standardized micro-fabricated structures.
3Manufacturing precision
If micro-chambers are used for production reactions, then matched HCVR-LCVR pairs are achieved, but the manufacturing cost increases
Solution Approach 1:
The micro-chamber design serves multiple functions: cell isolation, cDNA synthesis, and controlled ligation of heavy and light chains. This multi-functionality reduces the need for separate processing steps and equipment, thereby mitigating cost increases despite the precision enabled by the micro-chamber structure.
Solution Approach 2:
The method merges previously separate steps (cell isolation, cDNA synthesis, and chain linking) into an integrated micro-chamber workflow. By combining these functions into a single platform, the patent achieves precise HCVR-LCVR matching while reducing overall manufacturing complexity and cost compared to using separate specialized systems for each step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the generation of libraries of binding polypeptides that can be used to treat, prevent, and diagnose disorders by ensuring matched heavy and light chain sequences, enhancing the specificity and efficacy of monoclonal antibody therapies.
Implementation Method 1
an isolated production reaction site (e.g., a production micro-chamber) comprising: a heavy chain (HC) strand, wherein the HC strand is a strand of a heavy chain double-stranded cDNA (HC ds cDNA)
Implementation Method 2
covalent linking, e.g., ligation, of an HC strand to an LC strand
Data Source
AI summary
Polypeptides, such as antibody molecules and TCR molecules, and methods of making the same, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.